KSHV requires vCyclin to overcome replicative senescence in primary human lymphatic endothelial cells

English version

Autoři: Terri A. DiMaio ^aff001; Daniel T. Vogt ^aff001; Michael Lagunoff ^aff001
Působiště autorů: Department of Microbiology, University of Washington, Seattle, Washington, United states of America ^aff001
Vyšlo v časopise: KSHV requires vCyclin to overcome replicative senescence in primary human lymphatic endothelial cells. PLoS Pathog 16(6): e32767. doi:10.1371/journal.ppat.1008634
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.ppat.1008634

Souhrn

Kaposi’s Sarcoma Herpesvirus (KSHV) is present in the main tumor cells of Kaposi’s Sarcoma (KS), the spindle cells, which are of endothelial origin. KSHV is also associated with two B-cell lymphomas, Primary Effusion Lymphoma (PEL) and Multicentric Castleman’s Disease. In KS and PEL, KSHV is primarily latent in the infected cells, expressing only a few genes. Although KSHV infection is required for KS and PEL, it is unclear how latent gene expression contributes to their formation. Proliferation of cancer cells occurs despite multiple checkpoints intended to prevent dysregulated cell growth. The first of these checkpoints, caused by shortening of telomeres, results in replicative senescence, where cells are metabolically active, but no longer divide. We found that human dermal lymphatic endothelial cells (LECs) are more susceptible to KSHV infection than their blood-specific endothelial cell counterparts and maintain KSHV latency to higher levels during passage. Importantly, KSHV infection of human LECs but not human BECs promotes their continued proliferation beyond this first checkpoint of replicative senescence. The latently expressed viral cyclin homolog is essential for KSHV-induced bypass of senescence in LECs. These data suggest that LECs may be an important reservoir for KSHV infection and may play a role during KS tumor development and that the viral cyclin is a critical oncogene for this process.

Klíčová slova:

Cell cycle and cell division – Cell staining – Endothelial cells – Gene expression – Kaposi sarcoma – Kaposi's sarcoma-associated herpesvirus – Telomeres – Viral replication

Zdroje

1. Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998 Apr 15;58(8):1599–604. 9563467

2. Skobe M, Brown LF, Tognazzi K, Ganju RK, Dezube BJ, Alitalo K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol. 1999 Dec;113(6):1047–53. doi: 10.1046/j.1523-1747.1999.00798.x 10594750

3. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999 Feb;79(2):243–51. 10068212

4. Reis RM, Reis-Filho JS, Longatto Filho A, Tomarev S, Silva P, Lopes JM. Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors. Pathol Res Pract. 2005;201(12):771–6. doi: 10.1016/j.prp.2005.08.010 16308102

5. Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan JS, Greenspan D. Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells. Am J Pathol. 1993 Jul;143(1):240–9. 8100400

6. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995 May 4;332(18):1186–91. doi: 10.1056/NEJM199505043321802 7700311

7. Said W, Chien K, Takeuchi S, Tasaka T, Asou H, Cho SK, et al. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood. 1996 Jun 15;87(12):4937–43. 8652805

8. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995 Aug 15;86(4):1276–80. 7632932

9. Regulski MJ. Cellular Senescence: What, Why, and How. Wounds. 2017 Jun;29(6):168–174. 28682291

10. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001 Jan;75(1):429–38. doi: 10.1128/JVI.75.1.429-438.2001 11119611

11. Baresova P, Musilova J, Pitha PM, Lubyova B. p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3. Mol Cell Biol. 2014 Feb;34(3):386–99. doi: 10.1128/MCB.01011-13 Epub 2013 Nov 18. 24248600

12. Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 2007 Apr;117(4):1019–28. Epub 2007 Mar 15. doi: 10.1172/JCI30945 17364023

13. Granato M, Gilardini Montani MS, Santarelli R, D'Orazi G, Faggioni A, Cirone M. Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death. J Exp Clin Cancer Res. 2017 Nov 28;36(1):167. doi: 10.1186/s13046-017-0632-z 29179721

14. Ye F, Lattif AA, Xie J, Weinberg A, Gao S. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. Cell Cycle. 2012 Apr 1;11(7):1393–9. doi: 10.4161/cc.19756 Epub 2012 Apr 1. 22421142

15. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000 Oct;6(10):1121–7. doi: 10.1038/80459 11017143

16. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999 Dec 23–30;402(6764):889–94. doi: 10.1038/47266 10622254

17. Wong LY, Matchett GA, Wilson AC. Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol. 2004 Sep;78(18):10074–85. doi: 10.1128/JVI.78.18.10074-10085.2004 15331740

18. Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J Gen Virol. 2004 Jun;85(Pt 6):1347–61. doi: 10.1099/vir.0.79812-0 15166416

19. Jones T, Ramos da Silva S, Bedolla R, Ye F, Zhou F, Gao SJ. Viral cyclin promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact inhibition. Cell Cycle. 2014;13(5):845–58. doi: 10.4161/cc.27758 Epub 2014 Jan 13. 24419204

20. Koopal S, Furuhjelm JH, Järviluoma A, Jäämaa S, Pyakurel P, Pussinen C, et al. Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog. 2007 Sep 7;3(9):1348–60. doi: 10.1371/journal.ppat.0030140 17907806

21. Leidal AM, Cyr DP, Hill RJ, Lee PW, McCormick C. Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence. Cell Host Microbe. 2012 Feb 16;11(2):167–80. doi: 10.1016/j.chom.2012.01.005 22341465

22. Zhi H1, Zahoor MA1, Shudofsky AM1, Giam CZ1. KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-κB hyperactivation. Oncogene. 2015 Jan 22;34(4):496–505. doi: 10.1038/onc.2013.567 Epub 2014 Jan 27. 24469036

23. Carroll PA, Brazeau E, Lagunoff M. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004 Oct 10;328(1):7–18. doi: 10.1016/j.virol.2004.07.008 15380353

24. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004 Jul;36(7):683–5. Epub 2004 Jun 27. doi: 10.1038/ng1383 15220917

25. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Mäkinen T, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004 Jul;36(7):687–93. Epub 2004 Jun 27. doi: 10.1038/ng1384 15220918

26. Chang HH, Ganem D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe. 2013 Apr 17;13(4):429–40. doi: 10.1016/j.chom.2013.03.009 23601105

27. Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, et al. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002 Mar;76(5):2440–8. doi: 10.1128/jvi.76.5.2440-2448.2002 11836422

28. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest. 2004 Jan;113(1):124–36. doi: 10.1172/JCI17803 14702116

29. Golas G, Alonso JD, Toth Z. Characterization of de novo lytic infection of dermal lymphatic microvascular endothelial cells by Kaposi's sarcoma-associated herpesvirus. Virology. 2019 Jul 31;536:27–31. doi: 10.1016/j.virol.2019.07.028 31394409

30. Bruce AG, Barcy S, DiMaio T, Gan E, Garrigues HJ, Lagunoff M, et al. Quantitative Analysis of the KSHV Transcriptome Following Primary Infection of Blood and Lymphatic Endothelial Cells. Pathogens. 2017 Mar 19;6(1). pii: E11. doi: 10.3390/pathogens6010011 28335496

31. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 1997 May 1;99(9):2082–6. doi: 10.1172/JCI119380 9151779

32. Straface E, Vona R, Ascione B, Matarrese P, Strudthoff T, Franconi F, Malorni W. Single exposure of human fibroblasts (WI-38) to a sub-cytotoxic dose of UVB induces premature senescence. FEBS Lett. 2007 Sep 4;581(22):4342–8. Epub 2007 Aug 14. doi: 10.1016/j.febslet.2007.08.006 17716665

33. Nassour J, Radford R, Correia A, Fusté JM, Schoell B, Jauch A, Shaw RJ, Karlseder J. Nature. 2019 Jan;565(7741):659–663. doi: 10.1038/s41586-019-0885-0 Epub 2019 Jan 23. Autophagic cell death restricts chromosomal instability during replicative crisis. 30675059

34. Hayashi MT1, Cesare AJ2, Rivera T3, Karlseder J3. Nature. 2015 Jun 25;522(7557):492–6. doi: 10.1038/nature14513 Cell death during crisis is mediated by mitotic telomere deprotection. 26108857

35. Jain V1, Plaisance-Bonstaff K2, Sangani R3, Lanier C4, Dolce A5, Hu J6, Brulois K7, Haecker I8, Turner P9, Renne R10,11,12, Krueger B13. A Toolbox for Herpesvirus miRNA Research: Construction of a Complete Set of KSHV miRNA Deletion Mutants. Viruses. 2016 Feb 19;8(2). pii: E54. doi: 10.3390/v8020054 26907327

36. Choi HS, Jain V, Krueger B, Marshall V, Kim CH, Shisler JL, Whitby D, Renne R. Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Induces the Oncogenic miR-17-92 Cluster and Down-Regulates TGF-β Signaling. PLoS Pathog. 2015 Nov 6;11(11):e1005255. doi: 10.1371/journal.ppat.1005255 26545119

37. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 2008 Jun 15;68(12):4640–8. doi: 10.1158/0008-5472.CAN-07-5988 18559509

38. Petre CE1, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol. 2007 Feb;81(4):1912–22. Epub 2006 Nov 22. doi: 10.1128/JVI.01757-06 17121789

39. Punjabi AS, Carroll PA, Chen L, Lagunoff M. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol. 2007 Mar;81(5):2449–58. Epub 2006 Dec 6. doi: 10.1128/JVI.01769-06 17151100

40. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005 Sep;25(17):7432–4 doi: 10.1128/MCB.25.17.7432-7440.2005 16107692

41. Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, et al. Construction and manipulation of a new Kaposi’s sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol. 2012;86(18):9708–20. doi: 10.1128/JVI.01019-12 22740391

42. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 2003 Jan 15;31(2):E3–3 doi: 10.1093/nar/gng003 12527792

Článek A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection

Článek Translational profiling of macrophages infected with Leishmania donovani identifies mTOR- and eIF4A-sensitive immune-related transcripts

Článek Various miRNAs compensate the role of miR-122 on HCV replication

Článek HIV-1 variants are archived throughout infection and persist in the reservoir

Článek Novel partiti-like viruses are conditional mutualistic symbionts in their normal lepidopteran host, African armyworm, but parasitic in a novel host, Fall armyworm

Článek Microbiome factors in HPV-driven carcinogenesis and cancers

Článek Head-to-head comparisons of Toxoplasma gondii and its near relative Hammondia hammondi reveal dramatic differences in the host response and effectors with species-specific functions

Článek Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation

Článek Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis

Článek Different roles of integrin-β1 and integrin-αv for type IV secretion of CagA versus cell elongation phenotype and cell lifting by Helicobacter pylori

Článek Tn-Seq reveals hidden complexity in the utilization of host-derived glutathione in Francisella tularensis

Článek Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB